Herceptin, one of the first targeted cancer therapies, started with the discovery of a new gene with unexpectedly higher expression in breast cancer cells compared to healthy ones. This discovery led scientists to a new antibody that slowed breast cancer progression and extended survival in clinical trials. Herceptin has turned human epidermal growth factor receptor 2 (HER2)-positive breast cancer into one of the most treatable breast cancer forms.
Download this milestone article from Drug Discovery News to learn about Herceptin's development and how it revolutionized cancer treatment.